Get complimentary samples of Lo Loestrin® Fe and Minastrin® 24 Fe. Please see full Prescribing Information, including Boxed Warning.
 

Low-dose options

Lo Loestrin Fe

Only available ultra-low-dose OC with just 10 mcg of daily ethinyl estradiol in a 24/2/2 regimen1,2

Minastrin 24 Fe

Low-dose, 20 mcg-option with 24/4 dosing7

Request Samples

To receive your samples of Lo Loestrin Fe and Minastrin 24 Fe, click the “order samples” button.
Please print out the form provided and fax the completed form to 1-877-801-9949.

Order Samples

IMPORTANT RISK INFORMATION More Less

 
INDICATIONS AND USAGE
Lo Loestrin® Fe and Minastrin® 24 Fe are estrogen/progestin combination oral contraceptives (COCs) indicated for use by females of reproductive age to prevent pregnancy. Efficacy in women with a body mass index (BMI) of more than 35 kg/m2 has not been evaluated.
IMPORTANT SAFETY INFORMATION
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.

Contraindications
Lo Loestrin Fe or Minastrin 24 Fe are contraindicated in pregnant patients, and those with a high risk of arterial or venous thrombotic diseases, liver tumors (benign or malignant) or liver disease, undiagnosed abnormal uterine bleeding, or breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past.

Warnings and Precautions
Discontinue Lo Loestrin Fe or Minastrin 24 Fe if a thrombotic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Lo Loestrin Fe or Minastrin 24 Fe should not be started any earlier than 4 weeks after delivery, in women who are not breastfeeding. If jaundice occurs, treatment should be discontinued.

Lo Loestrin Fe or Minastrin 24 Fe should not be prescribed for women with uncontrolled hypertension or hypertension with vascular disease. Women who are pre-diabetic or diabetic, should be monitored while using Lo Loestrin Fe or Minastrin 24 Fe. Alternate contraceptive methods should be considered for women with uncontrolled dyslipidemia. Patients using Lo Loestrin Fe or Minastrin 24 Fe who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated.

Adverse Reactions
In the clinical trial for Lo Loestrin Fe, the most common adverse reactions (incidence ≥2%) were nausea/vomiting, headache, bleeding irregularities, dysmenorrhea, weight fluctuation, breast tenderness, acne, abdominal pain, anxiety, and depression.

In the clinical trial for Minastrin 24 Fe, the most common adverse reactions (incidence ≥2%) were headache, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, bacterial vaginitis, abnormal cervical smear, acne, mood swings, and weight gain.

Lo Loestrin Fe or Minastrin 24 Fe will not protect against HIV infection (AIDS) or other sexually transmitted diseases.

Please see full Prescribing Information for Lo Loestrin Fe or full Prescribing Information for Minastrin 24 Fe, including Boxed Warning.

REFERENCES
  1. Lo Loestrin® Fe prescribing information. Rockaway, NJ: Warner Chilcott (US), LLC; 2012.
  2. US Food and Drug Administration. Guidance for industry: labeling for combined oral contraceptives. http://www.fda.gov/downloads/Drugs/Guidance/ComplianceRegulatoryInformation/Guidances/ucm075075.pdf. Published March 2004. Accessed May 21, 2014.
  3. Data on file. Rockaway, NJ: Warner Chilcott (US), LLC.
  4. The Alan Guttmacher Institute. Fulfilling the promise: public policy and U.S. family planning clinics. http://www.guttmacher.org/pubs/fulfill.pdf. Accessed June 26, 2014.
  5. Oral contraceptive survey. Harris Poll. July 2014.
  6. Sech L, Segall-Gutierrez P, Silverstein E, et al. Oral contraceptives. The Merck Manual Web site. http://www.merckmanuals.com/professional/gynecology_and_obstetrics/family_planning/oral_contraceptives.html#v8579722. Updated August 2013. Accessed January 29, 2014.
  7. Minastrin® 24 Fe prescribing information. Rockaway, NJ: Warner Chilcott (US), LLC; 2013.